Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma

Gynecologic Oncology

Volumn 71, Issue 2, 1998, Pages 270-277

  Varia, Mahesh A ^a   Calkins Adams, Dennise P ^a   Rinker, Lillian H ^a   Kennedy, Andrew S ^a   Novotny, Debra B ^a   Fowler Jr , Wesley C ^a   Raleigh, James A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIMONIDAZOLE;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA STRAND BREAKAGE; HUMAN; HUMAN TISSUE; HYPOXIA; IMAGE ANALYSIS; OXYGENATION; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; TUMOR GROWTH; UTERINE CERVIX CANCER;

EID: 0032211938     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5163     Document Type: Article

References (30)

1. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 6:1996;3-9.
2. Sutherland R M, Ausserer W A, Murphy B J, Laderoute K R. Tumor hypoxia and heterogeneity: Challenges and opportunities for the future. Semin Radiat Oncol. 6:1996;59-70.
3. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
4. Tannock I. Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interactions of the drugs with radiation. Cancer Res. 42:1982;4921-4926.
5. Graeber T G, Osmanian C, Jacks T, Housman D E, Koch C J, Lowe S W, Giaccia A J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
6. Young S D, Marshall R S, Hill R P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA. 85:1988;9533-9537.
7. Brizel D, Sibley G, Prosnitz L, Scher R, Dewhirst M. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 38:1997;285-289.
8. Hall E J. Radiobiology for the Radiologist. 1994;Lippincott, Philadelphia.
9. Raleigh J A, Dewhirst M W, Thrall D E. Measuring tumor hypoxia. Semin Radiat Oncol. 6:1996;37-45.
10. Raleigh J A, Miller G G, Franko A J, Koch C J, Fuciarelli A F, Kelly D A. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br J Cancer. 56:1987;395-400.
11. Arteel G E, Thurman R G, Yates J M, Raleigh J A. Evidence that hypoxia markers detect oxygen gradients in liver: Pimonidazole and retrograde perfusion of rat liver. Br J Cancer. 72:1995;889-895.
12. Azuma C, Raleigh J A, Thrall D E. Lifetime of hypoxic cells in spontaneous canine tumors. Radiat Res. 148:1996;35-42.
13. Kennedy A S, Raleigh J A, Perez G M, Calkins D P, Thrall D E, Novotny D B, Varia M A. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys. 37:1997;897-905.
14. Raleigh J A, Koch C J. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol. 40:1990;2457-2464.
15. Cline J M, Thrall D E, Rosner G L, Raleigh J A. Distribution of the hypoxia marker CC1-103F in canine tumors. Int J Radiat Oncol Biol Phys. 28:1994;921-933.
16. Raleigh J A, La Dine J K, Cline J M, Thrall D E. An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours. Br J Cancer. 69:1994;66-71.
17. Thrall D E, McEntee M C, Cline J M, Raleigh J A. ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation. Int J Radiat Oncol Biol Phys. 28:1994;649-659.
18. Garcia C F, Weiss L M, Lowder J, Komoroske C, Link M P, Levy R, Warnke R A. Quantitation and estimation of lymphocyte subsets in tissue sections: Comparison with flow cytometry. Am J Clin Pathol. 87:1987;470-477.
19. Saunders M I, Anderson P J, Bennett M H, Dische S, Minchinton A I, Stratford M RL. The clinical testing of Ro 03-8799: pharmacokinetics, toxicology, tissue and tumor concentrations. Int J Radiat Oncol Biol Phys. 10:1984;1759-1763.
20. Roberts J T, Bleehen N M, Workman P, Walton M I. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799. J Radiat Oncol Biol Phys. 10:1984;1755-1758.
21. Foley J, Ton T, Maronpot R, Butterworth B, Goldsworthy T. Comparison of proliferating cell nuclear antigen to tritiated thymidine as a marker of proliferating hepatocytes in rats. Environ Health Perspect. 101:1993;199-206.
22. Chou, S-C, Yates, J, Raleigh, J, Development of hypoxia markers for clinical use: Pimonidazole. 1996.
23. Raleigh J A, Zeman E M, Calkins D P, McEntee M C, Thrall D E. Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors. Acta Oncol. 34:1995;345-349.
24. Secomb T W, Hsu R, Ong E T, Gross J F, Dewhirst M W. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. 34:1995;313-316.
25. Vaupel P, Fortmeyer H P, Runkel S, Kallinowski F. Blood flow, oxygen consumption, and tissue oxygenation of human breast cancer xenografts in nude rats. Cancer Res. 47:1987;3496-3503.
26. 2. Strahlenther Onkol. 173:1997;385-387.
27. Gross M W, Karbach U, Groebe K, Franko A J, Mueller-Klieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer. 61:1995;567-573.
28. Cline J, Rosner G, Raleigh J, Thrall D. Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int J Radiat Oncol Biol Phys. 37:1997;655-662.
29. Brown J M, Siim B G. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol. 6:1996;22-36.
30. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc Natl Acad Sci USA. 92:1995;768-772.